↓ Skip to main content

Dove Medical Press

Article Metrics

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis

Overview of attention for article published in Therapeutics and Clinical Risk Management, November 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (57th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
43 Mendeley
Title
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
Published in
Therapeutics and Clinical Risk Management, November 2015
DOI 10.2147/tcrm.s55928
Pubmed ID
Authors

Ori Elkayam, Ofir Elalouf

Abstract

The introduction of TNFα blockers has revolutionized the treatment of ankylosing spondylitis (AS). The objectives of this review are to summarize the most up-to-date data on long-term efficacy and safety of infliximab in AS, with special emphasis on axial and extra-articular disease, predictors of response, and radiological response. The general consensus of this literature search was that infliximab is highly efficacious in the treatment of AS. Most studies have demonstrated good clinical outcomes after 3 years of treatment, as measured by Spondyloarthritis International Society response in 75%-85% of treated AS patients. Reports on the long-term effects of infliximab as documented by radiological findings, however, are controversial. While some studies reported a similar progression rate as that of the historical OASIS cohort, others have suggested that infliximab may halt new bone formation. The long-term safety of infliximab is well known, mainly from data stored in national registries. While it has been suggested that side effects of infliximab may be fewer in AS compared to rheumatoid arthritis, data on this issue are sparse, with most of the information on long-term safety pertaining to rheumatoid arthritis. It can however be concluded that the long-term efficacy of infliximab is apparently maintained in AS and with an acceptable safety profile.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 2%
Mauritius 1 2%
Unknown 41 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 16%
Student > Master 6 14%
Student > Bachelor 6 14%
Researcher 5 12%
Student > Doctoral Student 5 12%
Other 6 14%
Unknown 8 19%
Readers by discipline Count As %
Medicine and Dentistry 20 47%
Pharmacology, Toxicology and Pharmaceutical Science 7 16%
Immunology and Microbiology 2 5%
Social Sciences 2 5%
Agricultural and Biological Sciences 1 2%
Other 2 5%
Unknown 9 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2015.
All research outputs
#7,046,733
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#437
of 922 outputs
Outputs of similar age
#140,366
of 340,300 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#22
of 57 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,300 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.